BioXcel Therapeutics (BTAI) Invested Capital (2017 - 2026)

BioXcel Therapeutics' Invested Capital history runs 10 years deep, the most recent figure standing at -$83.1 million for Q1 2026.

• In Q1 2026, Invested Capital rose 1.72% year-over-year to -$83.1 million; the TTM figure through Mar 2026 stood at -$83.1 million (up 1.72% YoY), while the FY2025 annual figure was -$70.5 million, down 617.82% from the prior year.
• Invested Capital was -$83.1 million for Q1 2026 at BioXcel Therapeutics, down from -$70.5 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $234.3 million in Q2 2022 to a low of -$96.5 million in Q2 2025.
• Historically, Invested Capital has averaged $53.1 million across 5 years, with a median of $31.5 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Invested Capital increased 3.93% in 2022, then sank 617.82% in 2025.
• A 5-year view of Invested Capital shows it stood at $178.2 million in 2022, then plunged by 74.09% to $46.2 million in 2023, then sank by 70.5% to $13.6 million in 2024, then tumbled by 617.82% to -$70.5 million in 2025, then slipped by 17.84% to -$83.1 million in 2026.
• The last three Invested Capital figures came in at -$83.1 million (Q1 2026), -$70.5 million (Q4 2025), and -$72.1 million (Q3 2025), per Business Quant data.